Cargando…

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis

Despite the availability of multiple disease-modifying therapies for relapsing multiple sclerosis (MS), there remains a need for highly efficacious targeted therapy with a favorable benefit–risk profile and attributes that encourage a high level of treatment adherence. Daclizumab is a humanized mono...

Descripción completa

Detalles Bibliográficos
Autor principal:	Cohan, Stanley
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026217/ https://www.ncbi.nlm.nih.gov/pubmed/27672308 http://dx.doi.org/10.2147/BTT.S89218

Ejemplares similares

Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis
por: Cohan, Stanley L., et al.
Publicado: (2019)

Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
por: Reardon, Jennifer, et al.
Publicado: (2013)

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2016)

Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
por: Benedict, Ralph HB, et al.
Publicado: (2017)

Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
por: Tran, Jonathan Q, et al.
Publicado: (2016)

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
por: Kappos, Ludwig, et al.
Publicado: (2021)

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016)

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013)

Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
por: Lin, Yen Chih, et al.
Publicado: (2015)

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2020)

Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis
por: Karunaratne, Kushan, et al.
Publicado: (2021)

Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis
por: Cohan, Stanley, et al.
Publicado: (2015)

Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis
Publicado: (2021)

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison
por: Cohan, Stanley, et al.
Publicado: (2021)

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE
por: Cohan, Stanley, et al.
Publicado: (2017)

Pharmacodynamic effects of daclizumab in the intrathecal compartment
por: Komori, Mika, et al.
Publicado: (2017)

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
por: Elkins, J., et al.
Publicado: (2015)

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
por: Bar-Or, Amit, et al.
Publicado: (2018)

Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis
por: Kramer, John, et al.
Publicado: (2023)

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis
por: Krueger, James G., et al.
Publicado: (2016)

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
por: Jankovic, Slobodan M
Publicado: (2010)

The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide
por: Cohan, Stanley, et al.
Publicado: (2021)

An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis
por: Fronza, Marzia, et al.
Publicado: (2021)

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
por: Cohan, Stanley L, et al.
Publicado: (2019)

Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND
por: Repovic, Pavle, et al.
Publicado: (2020)

Results of sustained long-term use of interferon beta-1a in a community-based cohort of patients with relapsing multiple sclerosis
por: Cohan, Stanley, et al.
Publicado: (2015)

Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment
por: Caporro, Matteo, et al.
Publicado: (2014)

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation
por: Sageshima, Junichiro, et al.
Publicado: (2009)

A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Tolley, Keith, et al.
Publicado: (2015)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article
por: Cohan, Stanley, et al.
Publicado: (2020)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015)

Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
por: Guarnera, Cristina, et al.
Publicado: (2017)

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
por: Guarnera, Cristina, et al.
Publicado: (2017)

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
por: Scheibe, Franziska, et al.
Publicado: (2018)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Factors Involved in Relapse of Multiple Sclerosis
por: Kamel, Fatemah Omar
Publicado: (2019)

Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry
por: Stuchiner, Tamela, et al.
Publicado: (2020)

Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
por: Carlström, Karl E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1gdq9fup5g9k32pv2j4mh4qsb3